Cancer Biology in Animals: From Mutation to Metastasis

Oncogenes, tumour suppressor genes, the hallmarks of cancer, angiogenesis, the metastatic cascade, and the tumour microenvironment — a mechanistic framework for understanding veterinary oncology.

Introduction: Cancer as a Cellular Rebellion

Cancer is not one disease but hundreds, united by a common cellular logic: the progressive acquisition of mutations that liberate a cell from the regulatory constraints that keep normal tissues orderly. Cancer cells are selfish — they divide when they should not, survive when they should die, invade where they should not go, and seduce normal cells into supporting their growth.

In this article, we examine cancer from the ground up: the types of mutations that drive it, the oncogenes and tumour suppressors that are its molecular engine, the hallmarks framework that unifies diverse cancers, the process of angiogenesis and metastasis, and the tumour microenvironment that sustains it all. We draw on veterinary examples throughout — canine mast cell tumours, feline vaccine-associated sarcomas, bovine ocular squamous cell carcinoma — because the biology is the same across species, and because our patients provide powerful models for understanding human cancer.

The Genetic Basis of Cancer: Oncogenes and Tumour Suppressors

Driver Mutations vs Passenger Mutations

A typical cancer genome contains thousands of mutations, but only a handful — typically 2–8 — are 'driver' mutations that directly contribute to the malignant phenotype. The rest are 'passengers' — incidental mutations acquired during the clonal expansion of a genomically unstable cell population. Identifying driver mutations is the goal of cancer genomics; targeting their protein products is the goal of precision oncology.

Oncogenes: The Accelerators Stuck 'ON'

Proto-oncogenes are normal cellular genes that promote cell division and survival. A single gain-of-function mutation in one allele is sufficient to convert a proto-oncogene into an oncogene — they are genetically DOMINANT. Mechanisms of activation include: (1) point mutations (Ras G12V locks Ras in the GTP-bound, active state), (2) gene amplification (Myc amplification in lymphoma — the MYC gene copy number increases 10–50×), (3) chromosomal translocations (BCR-ABL fusion in chronic myeloid leukaemia produces a constitutively active tyrosine kinase), and (4) activating mutations in the juxtamembrane domain (c-Kit D816V mutation in canine mast cell tumours).

Tumour Suppressor Genes: The Brakes That Fail

Tumour suppressor genes normally restrain cell division, promote DNA repair, or trigger apoptosis. They are genetically RECESSIVE — BOTH alleles must be inactivated for loss of function (Knudson's two-hit hypothesis). The first hit is typically a point mutation or small deletion; the second hit is loss of heterozygosity (LOH) — deletion of the remaining wild-type allele.

The Hallmarks of Cancer: A Unified Framework

In their landmark 2000 review (updated 2011, 2022), Hanahan and Weinberg proposed that all cancers share a set of acquired capabilities — the 'hallmarks of cancer.' This framework has become the central organising principle of cancer biology. The original six hallmarks were: (1) sustaining proliferative signalling, (2) evading growth suppressors, (3) resisting cell death, (4) enabling replicative immortality, (5) inducing angiogenesis, and (6) activating invasion and metastasis. Four emerging hallmarks were added later: deregulating cellular energetics, avoiding immune destruction, tumour-promoting inflammation, and genome instability and mutation.

1. Sustaining Proliferative Signalling

Normal cells require mitogenic growth signals to divide. Cancer cells acquire the ability to proliferate without external signals through: autocrine signalling (the cancer cell produces its own growth factors), overexpression of growth factor receptors (EGFR, HER2 amplification), constitutive activation of downstream signalling pathways (Ras mutations, c-Kit mutations), and disruption of negative feedback loops.

2. Evading Growth Suppressors

Normal cells are restrained by tumour suppressors — Rb (the G1/S checkpoint gatekeeper), p53 (the DNA damage sensor), and TGF-β (a potent growth inhibitor for epithelial cells). Cancer cells inactivate these pathways, liberating the cell cycle from external control.

3. Resisting Cell Death

Apoptosis is the default fate of cells that have sustained significant DNA damage or lost survival signals. Cancer cells evade apoptosis by: upregulating anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, Mcl-1), downregulating pro-apoptotic proteins (Bax, Bak, Bim), and inactivating p53 (which transcriptionally activates pro-apoptotic genes).

4. Enabling Replicative Immortality

Normal somatic cells have a finite replicative lifespan (~50–70 divisions, the Hayflick limit) determined by telomere shortening. Cancer cells activate telomerase (hTERT expression) to maintain telomere length, achieving unlimited replicative potential. Telomerase is activated in ~85% of canine malignancies.

5. Inducing Angiogenesis

(Covered in depth in the next section.)

6. Activating Invasion and Metastasis

(Covered in depth in the metastasis section.)

Angiogenesis: Building the Tumour's Blood Supply

A tumour cannot grow beyond approximately 1–2 mm³ without its own blood supply — the diffusion limit for oxygen. Early tumours exist in a state of equilibrium: proliferation is balanced by apoptosis, and the tumour remains dormant. The transition to an actively growing, clinically detectable tumour requires the 'angiogenic switch' — the upregulation of pro-angiogenic factors (VEGF, bFGF, PDGF) relative to anti-angiogenic factors (thrombospondin-1, angiostatin, endostatin).

Hypoxia is the master trigger. As the tumour outgrows its diffusion-limited oxygen supply, the transcription factor HIF-1α (hypoxia-inducible factor 1-alpha) is stabilised (normally it is rapidly degraded under normoxic conditions by the VHL ubiquitin ligase). HIF-1α transcriptionally activates VEGF, PDGF, and other angiogenic factors. Tumour blood vessels are abnormal — tortuous, leaky, poorly organised, with discontinuous pericyte coverage — which actually perpetuates hypoxia and VEGF production in a vicious cycle.

The Metastatic Cascade: A Journey of Extraordinary Inefficiency

Metastasis — the spread of cancer from the primary site to distant organs — is responsible for approximately 90% of cancer deaths in both human and veterinary patients. Yet it is an astonishingly inefficient process. Of the millions of tumour cells that enter the circulation daily from a primary tumour, fewer than 0.01% ever establish a clinically detectable metastasis. Every step of the cascade is a bottleneck.

1. Local invasion: Tumour cells breach the basement membrane by secreting matrix metalloproteinases (MMPs) that degrade the extracellular matrix. Epithelial-to-mesenchymal transition (EMT) — the loss of E-cadherin-mediated cell-cell adhesion and acquisition of a migratory, fibroblast-like phenotype — is a critical early step.
2. Intravasation: Tumour cells enter the blood or lymphatic circulation. They often co-opt macrophages to create 'doorways' through the vessel wall (the 'TMEM' — tumour microenvironment of metastasis).
3. Survival in circulation: Once in the bloodstream, tumour cells face shear stress, anoikis (apoptosis induced by loss of matrix attachment), and immune surveillance (NK cells). Only cells that express survival signals (TrkB, Bcl-2) and resist anoikis survive.
4. Arrest and extravasation: Tumour cells arrest in the capillary beds of target organs — mechanical trapping (size) and specific adhesion molecules (integrins, selectins). They then extravasate — migrate through the endothelial wall into the tissue parenchyma — using the same MMP-dependent mechanisms as intravasation.
5. Colonisation: The rate-limiting step. The tumour cell arrives in a foreign microenvironment that is hostile to its growth. It must adapt to the new tissue's growth factor milieu, extracellular matrix composition, and immune environment. This is the 'seed and soil' hypothesis (Paget, 1889): certain tumours ('seeds') preferentially metastasise to certain organs ('soil') — prostate cancer to bone, uveal melanoma to liver, osteosarcoma to lungs. Most disseminated tumour cells enter dormancy and never form macrometastases.

The Tumour Microenvironment: It Takes a Village

A tumour is not just a ball of cancer cells — it is a complex ecosystem comprising cancer cells, cancer-associated fibroblasts (CAFs), tumour-associated macrophages (TAMs), endothelial cells, pericytes, immune cells, and a remodelled extracellular matrix. The TME actively PROMOTES tumour progression — it is not a passive bystander.

Cancer-Associated Fibroblasts (CAFs)

CAFs are activated fibroblasts that deposit excessive extracellular matrix (desmoplasia), secrete growth factors (HGF, TGF-β, SDF-1) that promote tumour cell proliferation and invasion, and remodel the ECM to create 'tracks' for tumour cell migration. They are recruited and activated by tumour-derived PDGF and TGF-β.

Tumour-Associated Macrophages (TAMs)

Macrophages exist on a spectrum from M1 (pro-inflammatory, tumour-suppressive) to M2 (anti-inflammatory, tumour-promoting). TAMs are overwhelmingly M2-polarised — they secrete VEGF (angiogenesis), MMPs (invasion), IL-10 and TGF-β (immune suppression), and growth factors that directly stimulate tumour cell proliferation. High TAM density correlates with poor prognosis in canine mammary carcinoma, canine osteosarcoma, and feline injection-site sarcoma.

Immune Evasion: Avoiding Destruction

Cancer cells employ multiple strategies to evade the immune system: downregulation of MHC class I (reducing CD8⁺ T cell recognition), expression of PD-L1 (engaging PD-1 on T cells → T cell exhaustion), secretion of immunosuppressive cytokines (IL-10, TGF-β), and recruitment of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs). These mechanisms are the targets of cancer immunotherapy — checkpoint inhibitors (anti-PD-1, anti-PD-L1) unleash the pre-existing anti-tumour immune response.

Molecular Oncology: Targeted Therapies and Future Directions

Toceranib (Palladia) — Precision Medicine in Veterinary Oncology

Toceranib phosphate is a multikinase inhibitor with activity against: VEGFR-2, PDGFR-β, c-Kit, Flt-3, and CSF-1R. Its primary indication is canine mast cell tumours (MCTs) with activating c-Kit mutations — particularly internal tandem duplications (ITDs) in exon 11. The ITD disrupts the juxtamembrane autoinhibitory domain → constitutive kinase activation → persistent MAPK and PI3K/AKT signalling → uncontrolled proliferation and survival. Toceranib competitively binds the ATP-binding pocket of the c-Kit kinase domain → kinase inhibition → downstream signalling blockade → apoptosis of c-Kit-mutant MCT cells. Clinical response: ~60% objective response rate (complete + partial) in c-Kit-mutant MCTs vs ~30% in wild-type c-Kit MCTs. Adverse effects: GI toxicity (anorexia, vomiting, diarrhoea — common, usually manageable), muscle cramps, and a distinctive reversible depigmentation of the nasal planum and footpads (tyrosinase kinase inhibition → melanocyte dysfunction).

PARP Inhibitors and 'BRCAness' in Veterinary Oncology

BRCA1 and BRCA2 are tumour suppressor genes encoding proteins essential for homologous recombination (HR) repair of DNA double-strand breaks. Tumours with defective HR — whether from BRCA mutations or other defects in the HR pathway ('BRCAness' phenotype) — rely on alternative DNA repair pathways, particularly base excision repair (BER) mediated by poly(ADP-ribose) polymerase (PARP). PARP inhibitors (olaparib, rucaparib) exploit synthetic lethality: blocking BER in a cell that already has defective HR → overwhelming DNA damage → cell death. Normal cells (with intact HR) tolerate PARP inhibition. 'BRCAness' has been identified in some canine mammary carcinomas, haemangiosarcomas, and osteosarcomas — making PARP inhibitors a potential future therapy for selected veterinary cancer patients.

The Future: Liquid Biopsy, Neoantigen Vaccines, and CAR-T

Three emerging technologies are reshaping oncology. LIQUID BIOPSY: tumour-derived DNA fragments circulating in blood ('ctDNA') can be sequenced to detect mutations, monitor treatment response, and identify minimal residual disease — all without tissue biopsy. NEOANTIGEN VACCINES: tumour-specific mutations generate novel peptide sequences ('neoantigens') presented by MHC molecules. Sequencing the tumour genome → predicting which neoantigens will bind the patient's MHC → synthesising those peptides as a personalised vaccine → priming the patient's T cells to recognise and destroy tumour cells. CAR-T CELL THERAPY: the patient's own T cells are harvested, genetically modified to express a chimeric antigen receptor (CAR) that recognises a tumour-specific surface antigen (e.g., CD20 for B-cell lymphoma), expanded in vitro, and re-infused. The CAR-T cells then seek and destroy tumour cells. Canine CAR-T therapy for B-cell lymphoma is in clinical trials — using canine-specific anti-CD20 scFv fragments. The biology is the same; the species is different; the potential is enormous.

Cancer Genetics in Specific Veterinary Tumours: A Molecular Atlas

Veterinary oncology has entered the genomic era. The mutations driving the commonest canine and feline cancers are increasingly well-characterised, and many mirror the genetic landscape of the equivalent human tumours — reinforcing the One Health approach to cancer biology.

Cancer Stem Cells: The Root of Recurrence and Metastasis

The cancer stem cell (CSC) hypothesis proposes that within a tumour, only a small subpopulation of cells — the cancer stem cells — possess the capacity for unlimited self-renewal and differentiation that drives tumour growth, recurrence, and metastasis. The bulk of the tumour consists of non-tumorigenic progeny of these CSCs that have limited proliferative potential.

CSCs were first identified in acute myeloid leukaemia (CD34⁺/CD38⁻ cells) and have since been identified in solid tumours including breast, brain, colon, and prostate cancer. In veterinary oncology, CSC populations have been characterised in canine osteosarcoma (aldehyde dehydrogenase-high [ALDH-high] cells), canine mammary carcinoma (CD44⁺/CD24⁻ cells), and canine haemangiosarcoma (CD117⁺/CD34⁺ cells — an endothelial progenitor phenotype). CSCs are inherently resistant to conventional chemotherapy (they express high levels of drug efflux pumps — ABC transporters, particularly ABCG2 — and are predominantly quiescent, evading drugs that target cycling cells) and to radiotherapy (enhanced DNA repair capacity and reduced ROS production). This resistance explains why tumours frequently recur after apparently successful treatment — the bulk tumour cells are killed, but the CSCs survive to regenerate the tumour.

Therapeutic Implications of the CSC Hypothesis

If CSCs are the root of tumour recurrence and metastasis, then CSCs — not bulk tumour cells — are the critical therapeutic target. Strategies under investigation include: (1) Targeting CSC surface markers with monoclonal antibodies or CAR-T cells (e.g., anti-CD44, anti-CD133). (2) Inhibiting CSC self-renewal pathways — Notch, Wnt/β-catenin, and Hedgehog signalling are critical for CSC maintenance. (3) Inducing CSC differentiation with agents such as retinoic acid (as used in acute promyelocytic leukaemia) — 'differentiation therapy.' (4) Targeting the CSC niche — the specialised microenvironment that maintains CSCs. None of these approaches are yet approved in veterinary oncology, but the biology is conserved across species, and canine CSC research directly informs human trials.

Frequently asked questions

Self-check quiz

Test yourself. Answers are below each question — cover them first if you are studying.